The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Cholinergic influences in tardive dyskinesia

Published Online:https://doi.org/10.1176/ajp.134.7.769

The authors conducted placebo-controlled double-blind studies of physostigmine, choline, and deanol in 12 patients with tardive dyskinesia. Physostigmine and choline both had a positive therapeutic effect on tardive dyskinesia, but the authors note that interpretation of these results is not entirely clear because they found that the sedation effect of physostigmine may nonspecifically reduce the intensity of tardive dyskinesia symptoms. Deanol was not found to be effective in this group of patients; the authors suggest that this drug should not be assumed to be generally effective unless effectiveness is verified by a large placebo-controlled double-blind study.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.